Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04696055
Title Pilot Study of Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bayer
Indications

hepatocellular carcinoma

Therapies

Pembrolizumab + Regorafenib

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU


No variant requirements are available.